Table 1 Characteristics of enrolled patients in different treatment groups (N = 111)
Variables | Â | Total num | Chemo (n=45) | Chemo+Anti-angio (n=14) | Chemo+OSI (n=5) | Chemo+ICB (n=8) | OSI (n=24) | OSI+Anti-angio (n=11) | BSC (n=4) | P |
|---|---|---|---|---|---|---|---|---|---|---|
Gender | Male | 52 | 24 | 8 | 3 | 3 | 9 | 3 | 2 | 0.61 |
Female | 59 | 21 | 6 | 2 | 5 | 15 | 8 | 2 | Â | |
Age | <65 y.o. | 72 | 32 | 11 | 3 | 5 | 9 | 9 | 3 | 0.08 |
≥65 y.o. | 39 | 13 | 3 | 2 | 3 | 15 | 2 | 1 |  | |
ECOG PS | 0–1 | 91 | 35 | 12 | 3 | 7 | 21 | 10 | 3 | 0.72 |
2–3 | 20 | 10 | 2 | 2 | 1 | 3 | 1 | 1 |  | |
Smoking history | Non-smoke | 88 | 34 | 11 | 4 | 8 | 19 | 9 | 3 | 0.86 |
Smoke | 23 | 11 | 3 | 1 | 0 | 5 | 2 | 1 | Â | |
Histology | Adenocarcinoma | 100 | 38 | 13 | 5 | 8 | 23 | 10 | 3 | 0.54 |
NSCLC-NOS | 11 | 7 | 1 | 0 | 0 | 1 | 1 | 1 | Â | |
TMN stage | IIIB | 9 | 5 | 0 | 0 | 0 | 1 | 2 | 1 | 0.37 |
IV | 102 | 40 | 14 | 5 | 8 | 23 | 9 | 3 | Â | |
Biopsy specimens | Pulmonary tissue | 47 | 21 | 4 | 0 | 5 | 9 | 6 | 2 | 0.01 |
Blood | 42 | 19 | 3 | 3 | 1 | 13 | 1 | 2 | Â | |
Hydrothorax | 14 | 2 | 6 | 0 | 0 | 2 | 4 | 0 | Â | |
Lymph node | 6 | 2 | 1 | 1 | 2 | 0 | 0 | 0 | Â | |
Unknown | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | Â | |
Mutation type | 19Del+T790M | 71 | 26 | 12 | 3 | 6 | 16 | 6 | 2 | 0.56 |
L858R+T790M | 40 | 19 | 2 | 2 | 2 | 8 | 5 | 2 | Â | |
Metastasis before osimertinib treatment | No | 8 | 2 | 0 | 0 | 0 | 3 | 2 | 1 | 0.22 |
Intrapulmonary metastasis | 21 | 6 | 5 | 1 | 1 | 5 | 3 | 0 | Â | |
1–3 Extrapulmonary metastasis | 47 | 24 | 7 | 1 | 4 | 7 | 4 | 0 |  | |
>3 Extrapulmonary metastasis | 35 | 13 | 2 | 3 | 3 | 9 | 2 | 3 | Â | |
Progression patterns | Asymptomatic | 26 | 9 | 5 | 0 | 1 | 8 | 2 | 1 | 0.38 |
Brain metastasis | 4 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | Â | |
Systemic limited metastasis | 28 | 10 | 1 | 1 | 3 | 10 | 2 | 1 | Â | |
Systemic multiple lesions | 12 | 5 | 1 | 0 | 0 | 3 | 2 | 1 | Â | |
Unknown | 41 | 19 | 7 | 3 | 3 | 3 | 5 | 1 | Â | |
Re-biopsy | No | 70 | 30 | 9 | 5 | 3 | 14 | 7 | 2 | 0.43 |
Yes | 41 | 15 | 5 | 0 | 5 | 10 | 4 | 2 | Â | |
Resistance mechanism of osimertinib | On-target mutation | 11 | 4 | 1 | 0 | 0 | 4 | 2 | 0 | 0.37 |
Off-target mutation | 3 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | Â | |
SCLC transformation | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | Â | |
Unknown | 94 | 39 | 12 | 5 | 7 | 19 | 9 | 3 | Â | |
LCT | Yes | 20 | 8 | 1 | 1 | 2 | 7 | 1 | 0 | 0.56 |
No | 91 | 37 | 13 | 4 | 6 | 17 | 10 | 4 | Â |